Beijing Sihuan Pharmaceutical

Sihuan Pharmaceutical Holdings Group is a leading integrated pharmaceutical and medical aesthetics group in China with a strong focus on cardio-cerebral vascular (CCV), oncology, and diabetes treatments. The company has successfully transitioned from a traditional pharmaceutical firm to an innovation-led enterprise through its specialized subsidiaries, Xuanzhu Biopharmaceutical and Huisheng Biopharmaceutical. Sihuan is also a dominant player in China's medical aesthetics market, holding exclusive rights to the botulinum toxin product Letybo. Its extensive commercial network and robust R&D pipeline, which includes both small molecules and biologics, position it as a key player in the Chinese healthcare landscape. The group continues to expand its footprint in high-growth sectors like metabolic diseases and innovative oncology therapies.